ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1378

Low HDL Level As a Clinical Marker of Disease Activity in Rheumatoid Arthritis Patients

Rocío Gamboa-Cárdenas1, Manuel Ugarte-Gil2, Francisco Zevallos1, Mariela Medina1, Zoila Rodriguez-Bellido1, Claudia Elera-Fitzcarrald1, Omar Sarmiento-Velasquez1, Cristina Reategui-Sokolova1, Victor Pimentel-Quiroz1, José Alfaro1, Mariano Cucho-Venegas1, Risto Perich-Campos3 and Cesar A. Pastor-Asurza1, 1Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 2Peru, GLADEL, Lima, Peru, 3Rheumatology, Hospital Guillermo Almenara Irigoyen, Lima, Peru

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In contrast to high evidence of HDL inflammatory function in cardiovascular risk in rheumatoid arthritis (RA) patients, there is scarce data about the total HDL levels as a marker of RA disease activity.

Methods: A cross-sectional study in Rheumatology department of Hospital Almenara EsSalud. Lima Perú. Subjects were recruited consecutively from our RA cohort. RA was defined with ACR 87/ACR EULAR 2010 RA criteria, without overlap syndromes except Sjögren, current infections or pregnancy. For these analyses hospitalized patients, with recent medical/surgical procedures or severe anemia (less than 7 g/dL) were excluded. Clinical interview, chart review, physical examination (included 28 joint count), health questionnaires, Visual analogue scales and laboratory sampling including a complete lipid profile were performed in the same day. A univariable and multivariable linear regression models were performed in order to determine if HDL levels were associated with disease activity (DAS 28 or CDAI) independently of disease duration, gender, age at diagnosis, socioeconomic status, use of conventional DMARDs, biologics, current corticosteroid dose, CRP, anti CCP, RF, and metabolic syndrome.

Results:

Results: Two hundred and seventy-eight patients were included, all Mestizos, 92.8% were female, disease duration was 15.16 (11.92) and age at diagnosis 44.08 (13.92) years. The most frequent socioeconomic statuses were low: 30.9%, middle 33.1% and high 33.8%. Current prednisone dose was 4.50 mg/d (3.30). Patients with current convectional DMARD use were 97.1 % and 6.1 % with biologic agent; RF level was 290.39 (474, 17) UI/ml and anti CCP 544, 98 (132.37) U/ml. Level of HDL was 56.98 (1326, 37) mg/dL and LDL 120.76 (33.00) mg/L. One hundred and three patients (37.1 %) had metabolic syndrome. DAS 28 media score was 4.69 (1.22) and CRP level 11.76 (21.41) mg/dL. In the multivariate analysis HDL cholesterol level was associated with DAS 28 score (B= -0.016: CI: -0.26 – -0.01; p=0.04) independently of other variables. HDL cholesterol level was also independently associated with CDAI score (B -0.14 CI -0.24 – -0.04 p= 0.009)

Conclusion: Low HDL cholesterol level was associated with higher disease activity in RA patients, independently of other known classical factors. A more careful evaluation of active disease could be performed in patients with this potential marker, in clinical practice.


Disclosure: R. Gamboa-Cárdenas, None; M. Ugarte-Gil, None; F. Zevallos, None; M. Medina, None; Z. Rodriguez-Bellido, None; C. Elera-Fitzcarrald, None; O. Sarmiento-Velasquez, None; C. Reategui-Sokolova, None; V. Pimentel-Quiroz, None; J. Alfaro, None; M. Cucho-Venegas, None; R. Perich-Campos, None; C. A. Pastor-Asurza, None.

To cite this abstract in AMA style:

Gamboa-Cárdenas R, Ugarte-Gil M, Zevallos F, Medina M, Rodriguez-Bellido Z, Elera-Fitzcarrald C, Sarmiento-Velasquez O, Reategui-Sokolova C, Pimentel-Quiroz V, Alfaro J, Cucho-Venegas M, Perich-Campos R, Pastor-Asurza CA. Low HDL Level As a Clinical Marker of Disease Activity in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/low-hdl-level-as-a-clinical-marker-of-disease-activity-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-hdl-level-as-a-clinical-marker-of-disease-activity-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology